Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharmacology II > Antimicrobials > Flashcards

Antimicrobials Flashcards

Antifungals/Antiparasitics/Antivirals (132 cards)

Start Studying
1
Q

Fungal infections

A

most commonly superficial involving the skin but if systemic can be severe and life-threatening (often affecting immunocompromised patients)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Amphotericin B MOA

A

a polyene (produced by Streptomyces nodosus) that is a lipophilic rod-like molecule that disrupts fungal cell wall synthesis by binding to sterols, primarily ergosterol, leading to the formation of pores in the cell membrane resulting in K+ leaking out of the cell and causing death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Amphotericin B spectrum of activity

A

used to treat severe invasive fungal infections with the widest spectrum of activity of all antifungals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Amphotericin B pharmacokinetics

A

used IV which has wide tissue distribution with rapid onset of action and is not dependent on the organism’s growth rate, has poor oral absorption and little CSF penetration - narrow therapeutic index

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Amphotericin B adverse effects

A

reversible nephrotoxicity due to a dose-dependent decrease in GFR and vasoconstriction of afferent renal arterioles, infusion-related reactions (fever and rigors), nausea/vomiting, reversible anemia, phlebitis, and renal tubular acidosis with wasting of K+, Mg2+, and HCO3-

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Amphotericin B contraindications

A

use with cyclosporine, tacrolimus, aminoglycosides can exacerbate nephrotoxicity, pre-existing renal insufficiency, intravascular volume depletion - hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Flucytosine (5-FC) MOA

A

synthetic pyrimidine analog that inhibits thymidylate synthase and incorporates into fungal RNA disrupting nucleic acid and protein synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Flucytosine spectrum of activity

A

used in combination with amphotericin B (synergistic) to treat systemic mycoses and meningitis caused by cryptococcus and candida species and in combination with itraconazole to treat chromoblastomycosis infections (not used as monotherapy due to high resistance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Flucytosine resistance mechanism

A

fungi decrease the level of enzymes that are targeted by flucytosine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Flucytosine pharmacokinetics

A

has good oral absorption and penetrates CSF, dose adjustment required for renal impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Flucytosine adverse effects

A

most common are GI upset, N/V, and diarrhea, also reversible neutropenia, thrombocytopenia, dose-related bone marrow suppression, reversible hepatic dysfunction,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ketoconazole MOA

A

an imidazole that inhibits C-14 alpha-demethylase decreasing synthesis of ergosterol thereby disrupting membrane structure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Ketoconazole spectrum of activity

A

used topically and orally to treat Candida, Histoplasma, Blastomyces, and Coccidioides infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Ketoconazole contraindications

A

use with Amphotericin B and in pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Ketoconazole pharmacokinetics

A

requires gastric acid for dissolution and absorption (can’t be used with antacids, H2-histamine blockers, and PPIs), metabolized by CYP450 in the liver - low levels found in urine (cannot treat mycotic UTIs), does not penetrate CSF, inhibits human gonadal and adrenal steroid hormone synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ketoconazole resistance mechanism

A

mutations in the C-14 alpha-demethylase gene resulting in decreased binding of the drug and some strains have developed the ability to pump drug out of the cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Ketoconazole adverse effects

A

Gi upset most common, hepatitis (monitor LFTs), gynecomastia, decreased libido, menstrual irregularities due to endocrine effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

the Imidazoles

A

ketoconazole, miconazole, and clotrimazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

the Triazoles

A

fluconazole, itraconazole, voriconazole, and posaconazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Fluconazole MOA

A

a triazole that inhibits the synthesis of cell membranes via inhibition of C-14-alpha-demethylase, a fungal CYP450 enzyme similar to ketoconazole, however, it does not interfere with mammalian CYP450 enzymes involved in the synthesis of steroid hormones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Itraconazole MOA

A

a triazole that inhibits the synthesis of cell membranes via inhibition of C-14-alpha-demethylase, a fungal CYP450 enzyme similar to ketoconazole, however, it does not interfere with mammalian CYP450 enzymes involved in the synthesis of steroid hormones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Fluconazole spectrum of activity

A

used to treat Candida, Cryptococcus neoformans, and Coccidiomycosis infections (no activity against aspergillus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Fluconazole pharmacokinetics

A

available orally and IV and not dependent on gastric acid for absorption, has good CSF penetration, requires dose adjustment for renal impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Fluconazole adverse effects

A

nausea, vomiting, rashes, alopecia, rare hepatitis, teratogenic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Fluconazole contraindications
in pregnancy (teratogenic)
26
Itraconazole MOA
a triazole that inhibits the synthesis of cell membranes via fungal CYP450 inhibition similar to ketoconazole, however, it does not interfere with mammalian CYP450 enzymes involved in the synthesis of steroid hormones
27
Itraconazole spectrum of activity
broad spectrum of activity and is the drug of choice for the treatment of histoplasmosis, blastomycosis, Coccidioidomycosis, and sporotrichosis infections
28
Itraconazole pharmacokinetics
has good oral bioavailability but requires gastric acid for absorption (no IV formulation available), metabolized in the liver, does not require dose adjustment for renal impairment, does not penetrate CSF well
29
Itraconazole adverse effects
nausea, vomiting, rash, headache, hypertension, hypokalemia, edema, rare hepatitis, alopecia with chronic therapy, teratogenic
30
Itraconazole contraindications
in pregnancy (teratogenic), in patients with CHF or history of CHF
31
Caspofungin MOA
an echinocandins that inhibits B(1,3)-D-glucan synthase which is an enzyme involved in fungal wall synthesis
32
Caspofungin spectrum of activity
used to treat Candida glabrata infections and azole-resistant Candida esophagitis, used second line to treat invasive aspergillus infections (not active against Zygomycetes and Cryptococcus neoformans), has poor CNS penetration
33
Caspofungin adverse effects
generally well tolerated, only thing is histamine infusion reaction which can be pretreated with diphenhydramine
34
Caspofungin drug interactions
use with cyclosporine, tacrolimus, and rifampin
35
DOC for treatment for invasive aspergillus infections
Voriconazole
36
Nystatin MOA
a polyene that binds to ergosterol and disrupts fungal cell wall synthesis leading to the formation of pores in the cell membrane resulting in K+ leaking out of the cell and causing death
37
Nystatin clinical indications
used topically (powder, cream, ointment) or as an oral suspension to treat fungal skin/vaginal/mouth infections
38
Nystatin pharmacokinetics
too toxic for systemic use (never used IV), not absorbed from the GI tract
39
Griseofulvin MOA
inhibits mitosis by interfering with microtubules
40
Griseofulvin clinical indications
used to treat dermatophytic nail infections due to accumulation in keratin-containing tissues - treatment may be required for 6-12 months
41
Griseofulvin drug interactions
induces CYP450 and increases the rate of metabolism of other drugs including warfarin
42
Itraconazole drug interactions
warfarin, statins, and phenytoin
43
Ketoconazole drug interactions
cyclosporine, phenytoin, tolbutamide, warfarin, and rifampin
44
Terbinafine MOA
inhibits cell wall synthesis by inhibiting fungal squalene epoxidase decreasing the synthesis of ergosterol
45
Terbinafine clinical indications
DOC for treatment of onychomycosis and dermatophytic infections due to accumulation in skin, nails, and fat
46
Terbinafine contraindications
in nursing mothers due to accumulation in breast milk
47
Terbinafine adverse effects
hepatotoxicity - needs LFTs at baseline
48
DOC for the treatment of Coccidioidomycosis
Fluconazole or Itraconazole, if severe/disseminated then Amphotericin B
49
DOC for the treatment of Histoplasmosis
Itraconazole
50
DOC for the treatment of Blastomycosis
Itraconazole
51
DOC for the treatment of Aspergillus
1st line = Voriconazole, then Posaconazole, then Caspofungin, and then Amphotericin B
52
DOC for the treatment of Zygomycetes
1st line = Posaconazole, then Amphotericin B
53
Metronidazole MOA
contains a nitro group that serves as an electron acceptor and forms toxic metabolites that disrupt DNA helical structure leading to cell death when activated by anaerobes
54
Metronidazole spectrum of activity
active against amebiasis, giardiasis, trichomoniasis, and anaerobic bacteria, considered tissue agent and co-administered with luminal agent Paromomycin
55
Metronidazole pharmacokinetics
metabolized in liver and accumulates in patients with severe hepatic disease, excreted in urine
56
Metronidazole adverse effects
GI upset, metallic taste, seizures, neuropathy, disulfiram effect with alcohol
57
Griseofulvin contraindication
use with alcohol
58
Metronidazole contraindications
in pregnancy, breastfeeding, and in recent use with disulfiram
59
Alternatives to Metronidazole
tinidazole, ornidazole, and nitazoxanide
60
Trimethoprim-Sulfamethoxazole (TMP-SMX) MOA
combination of TMP-SMX provides sequential and synergistic blockade of folate pathway which leads to the inhibition of thymidine synthesis
61
TMP-SMX spectrum of activity
active against Cyclospora and Isospora infections
62
TMP-SMX adverse effects
rash, SJS, kernicterus, hemolysis in G6PD deficiency, bone marrow suppression, anemia, renal impairment, and hepatotoxicity
63
TMP-SMX contraindications
caution in patients with renal disease, contraindicated in newborns (<2 months) and pregnancy
64
TMP-SMX drug interactions
warfarin, phenytoin, and methotrexate
65
Albendazole MOA
binds to microtubules in intestinal and tegmental worms and larvae impairing glucose uptake, leading to glycogen depletion, degeneration of ER and mitochondria, release of lysosomes, and depletion on ATP/energy causing helminth/worm death
66
Albendazole spectrum of activity
broadly effective against nematode infections (roundworms)
67
Albendazole adverse effects
headache, elevated LFTs, rarely GI upset and alopecia, and very rarely liver failure, myelosuppression, and seizures, teratogenic
68
Albendazole contraindication
in pregnancy (teratogenic)
69
Pyrantel Pamoate MOA
causes the release of acetylcholine and inhibits cholinesterase, acts as a depolarizing neuromuscular blocker, and spastic paralysis and release of helminths
70
Pyrantel Pamoate spectrum of activity
alternative to albendazole therapy for the treatment of Enterobius vermicularis (pinworms) infections, however, not preferred agent
71
Pyrantel Pamoate adverse effects
rare headache, dizziness, and GI distress
72
Praziquantel MOA
increases cell permeability to Ca2+ in schistosomes causing strong contractions and paralysis of helminth musculature which leads to detachment, dislodgement, and death
73
Praziquantel spectrum of activity
active against cestodes (tapeworms) and trematodes (flukes and Schistosoma)
74
Praziquantel adverse effects
abdominal pain, dizziness, and drowsiness (CNS side effects such as headache and seizures in patients with cerebral cysticercosis from the death of the parasites)
75
Praziquantel pharmacokinetics
extensively metabolized by CYP3A4, avoid co-administration with CYP inducers
76
Ivermectin MOA
binds to and activates glutamate-gated chloride channels in invertebrate nerve and muscle cells causing hyperpolarization and death of the helminth, does not cross the BBB
77
Ivermectin spectrum of activity
active against strongyloidiasis and onchocerciasis (river blindness) and used topically for treatment of head lice
78
Ivermectin adverse effects
neurotoxicity (CNS depression, ataxia) from activation of GABA-ergic synapses and some cutaneous effects
79
Ivermectin contraindications
in pregnancy and meningitis
80
Oseltamivir MOA
inhibitor of neuraminidase which is an enzyme essential for cleaving the virus from the host cell and allowing the spread of the virus from cell to cell
81
Oseltamivir spectrum of activity
effective in decreasing Influenza A and B viral load and shortening the course of disease by 1-2 days if administered within 48 hours of symptoms onset, also can be administered prophylactically
82
Oseltamivir pharmacokinetics
administered orally and is a prodrug that is hydrolyzed in the liver to its active form, required dose adjustment in renal impairment
83
Oseltamivir adverse effects
most commonly nausea and/or vomiting (recommend taking with food to minimize GI effects)
84
Patients considered high risk for influenza complications
children < 2 years old or adults > 65 years old, persons with comorbidities or who are immunocompromised, pregnant women, persons morbidly obese, nursing home residents or residents of chronic care facilities
85
Acyclovir MOA
activated by viral thymidine kinase (TK) into acycloGTP (a guanosine analog) which inhibits viral DNA polymerase and terminates viral transcription
86
Acyclovir spectrum of activity
active against Herpes simplex viruses (HSV) 1 and 2 and Varicella-zoster (VZV) which causes chickenpox and zoster, no activity against CMV or latent Herpes viruses
87
Acyclovir pharmacokinetics
administered orally or through IV and metabolized by the kidneys, has poor oral bioavailability so requires frequent dosing, requires dose adjustment in renal impairment
88
Acyclovir adverse effects
generally well tolerated, more side effects with IV administration - most common is GI upset, nephrotoxicity due to IV acyclovir crystallization in renal tubules causing obstruction, and neurotoxicity causing lethargy, confusion, and delirium
89
Valacyclovir MOA
a valine ester of acyclovir and prodrug that is hydrolyzed by first-pass metabolism in the intestine and liver with a 99% conversion rate to acyclovir, requires less frequent dosing in comparison to acyclovir (but 5x more expensive)
90
Valacyclovir spectrum of activity
active against Herpes simplex viruses (HSV) 1 and 2 and Varicella-zoster (VZV) which causes chickenpox and zoster, no activity against CMV or latent Herpes viruses
91
Valacyclovir adverse effects
same adverse effects as acyclovir but headache more common with valacyclovir
92
Famciclovir MOA
metabolized to penciclovir via phosphorylation by viral thymidine kinase (TK) in infected cells which activates it where it then selectively inhibits viral DNA polymerase by termination of transcription
93
Famciclovir adverse effects
same as acyclovir
94
Famciclovir spectrum of activity
same as acyclovir
95
Acyclovir resistance mechanism
mutation or loss of viral thymidine kinase (TK) which is the first step in the phosphorylation of acyclovir with 6-8% incidence in immunocompromised hosts
96
Foscarnet MOA
inorganic pyrophosphate analog that directly inhibits DNA polymerase by reversibly blocking the pyrophosphate binding site of viral DNA polymerase (does not require activation by viral TK)
97
Foscarnet spectrum of activity
active against CMV retinitis and mucocutaneous acyclovir-resistant HSV in immunocompromised patients and VZV infections
98
Foscarnet pharmacokinetics
available only in IV form and requires dose adjustment for renal impairment
99
Foscarnet adverse effects
GI upset, electrolyte abnormalities including hypokalemia, hypocalcemia, hypomagnesemia, and hypophosphatemia, also reversible nephrotoxicity worsened by concomitant use of nephrotoxic agents (Amphotericin B, cyclosporine, tacrolimus, and aminoglycosides)
100
Interferons MOA
host cytokines (proteins) with complex antiviral, immunomodulatory, and anti-proliferative activities thought to induce gene transcription of host cell enzymes that inhibit viral RNA, increase phagocytic activity of macrophages, and increase cytotoxicity of lymphocytes for target cells
101
Interferons clinical indications
used to treat HBV and HCV as part of a combination but rarely used as first-line choice
102
Interferons adverse effects
flu-like symptoms shortly after admin, mood disorders, depression, somnolence, confusion, profound fatigue, weight loss, seizures, myelosuppression, rash, cough, myalgia, alopecia, tinnitus, reversible hearing loss, retinopathy, pneumonitis, cardiotoxicity, and autoimmune reaction
103
Interferons pharmacokinetics
administered IV or subcutaneously, no oral formulation, require dose adjustment with renal disease (if CrCl < 10)
104
Goals of HBV antiviral treatment
suppression of HBV DNA levels, seroconversion of HBeAg-positive to HBeAg-negative, loss of HBsAg detection, and decrease the risk of liver damage due to necrosis, failure, and hepatocellular carcinoma
105
Lamivudine MOA
cytosine analog that works to inhibit viral DNA synthesis by inhibiting HBV DNA polymerase, also works against HIV reverse transcriptase
106
Lamivudine clinical indications
used to treat chronic Hep B infections and may be used in combination with other Hep B antivirals in the treatment of HIV-HBV co-infections, requires HIV testing prior to treatment initiation
107
Lamivudine pharmacokinetics
has good oral bioavailability and requires dose adjustment in renal impairment (if CrCl < 50)
108
Lamivudine adverse effects
generally well tolerated, can cause headache, dizziness, pancreatitis, and rarely lactic acidosis and severe hepatomegaly
109
Entecavir MOA
phosphorylated to guanosine triphosphate (GTP) and competitively inhibits HBV DNA polymerase
110
Entecavir clinical indications
used to treat chronic Hep B infections and weakly active against HIV (not recommended for use in HIV-HBV co-infections without a fully suppressive anti-HIV regimen as it may cause resistance to lamivudine), also not preferred for lamivudine-resistant HBV strains
111
Entecavir pharmacokinetics
requires dose adjustment in renal impairment (CrCl < 50)
112
Entecavir adverse effects
may cause increased ALT levels, mild GI upset, mild hyperglycemia, headache, and rarely lactic acidosis and hepatomegaly
113
Tenofovir MOA
inhibits replication of HBV by inhibiting HBV DNA polymerase, also works against HIV reverse transcriptase
114
Tenofovir clinical indications
used to treat chronic Hep B infections and may be used in patients who have had prior treatment or developed drug resistance, preferred if there is lamivudine resistance, HIV testing required prior to treatment initiation
115
Tenofovir pharmacokinetics
2 formulations are available: tenofovir disoproxil fumarate and tenofovir alafenamide (associated with less renal and bone toxicity), dose adjustment is required in renal impairment (CrCl < 50)
116
Tenofovir adverse effects
GI upset, rash, hypercholesterolemia, decreased bone mineral density, and rarely lactic acidosis and hepatomegaly
117
Black Box Warning for anti-hep B therapy discontinuation
severe acute exacerbations of hepatitis have been reported in hepatitis B virus-infected patients who have discontinued anti-hep B therapy (must monitor liver function closely for several months in patients who discontinue therapy to avoid this)
118
Goal of chronic HCV treatment
eradicate the virus where the response to therapy is measured by looking at the sustained virologic response (SVR) which is determined by measuring HCV RNA (quantitative assay) and eradication = undetectable RNA levels after 12 weeks of therapy
119
Ribavirin MOA
inhibits guanine nucleotide synthesis thereby inhibiting viral transcription and RNA replication
120
Ribavirin clinical indications
used for the treatment of Hep C (oral administration in combo with interferon) and also may be used for the treatment of severe pediatric RSV infections (aerosol)
121
Ribavirin adverse effects
hemolytic anemia
122
Ledipasvir MOA
direct-acting antiviral that inhibits NS5A protein which plays a role in both Hep C viral replication and viral assembly
123
Ledipasvir pharmacokinetics
administered orally in combination with other direct-acting antivirals and also available in combination treatment with sofosbuvir, increased gastric pH levels may decrease absorption
124
Ledipasvir adverse effects
generally well tolerated, expensive
125
Sofosbuvir MOA
direct-acting antiviral that inhibits NS5B protein which plays a role in both Hep C viral replication and viral assembly
126
Sofosbuvir pharmacokinetics
administered orally in combination with ledipasvir and/or protease inhibitors, expensive
127
Sofosbuvir adverse effects
generally well tolerated but may cause fatigue, headache, and insomnia, if used with amiodarone can cause symptomatic bradycardia and a fatal cardiac arrest
128
Sofosbuvir contraindications/drug interactions
use with rifampin, rifapentine, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, and tipranavir/ritonavir (used for HIV)
129
Ledipasvir-Sofosbuvir clinical indications
administered orally as a single combination tablet with or without ribavirin for treatment of hepatitis C depending on the patient
130
Ledipasvir-Sofosbuvir adverse effects
generally well tolerated but can cause fatigue, headache, and insomnia
131
Ledipasvir-Sofosbuvir contraindications
avoid in patients with severe renal impairment (CrCl < 30) and coadministration with amiodarone due to symptomatic bradycardia and fatal cardiac arrest
132
Ledipasvir-Sofosbuvir drug interactions
potential drug interactions due to the presence of Sofosbuvir

Pharmacology II (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions